Benefit of a single intra-articular injection of hyaluronic acid in the treatment of osteoarthritis
Viscosupplementation serves as a minimally invasive procedure to restore the rheological properties of synovial fluid and alleviate pain in patients with symptomatic osteoarthritis (OA). We now have a new 3rd generation hyaluronic acid (HA) product for intra-articular injections – Hyruan One, which uses HA cross-linking technology. The following text summarizes its benefits in the pharmacological management of OA.
Possibility of single administration of HA
Thanks to cross-linking technology, this product exhibits a long-lasting pharmacological effect even with a single administration. The advantages of cross-linked HA over 1st and 2nd generation products (low-molecular-weight and high-molecular-weight HA) include a single-injection regimen, high viscoelasticity, long lifespan, and gel form.
Cross-linked HA in international recommendations
According to current recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) from 2016, intra-articular injection of HA is recommended for advanced pharmacological management in patients with persistent symptoms of osteoarthritis after intermittent or long-term cycles of oral non-steroidal anti-inflammatory drugs (NSAIDs).
Recommendations from the American Academy of Orthopaedic Surgeons (AAOS) indicate that meta-analyses of studies evaluating pain, functionality, and stiffness of joints affected by osteoarthritis (scores from subscales of the WOMAC index) consistently showed statistically significant effects of high-molecular-weight cross-linked HA.
Proven efficacy of cross-linked HA
In these meta-analyses, higher efficacy of cross-linked HA compared to non-cross-linked HA was observed after the 13th week of treatment. Cross-linked HA demonstrated significant pain relief compared to linear HA. Single-injection cross-linked HA showed greater and longer-lasting pain relief and less aggressive tissue reaction compared to repeated injections of non-cross-linked HA.
Single administration reduces the risk of injection-related infection and, in patients taking anticoagulants, also the risk of bleeding. It has been shown that single administration also reduces the risk of injection-related infection in patients undergoing chronic corticosteroid treatment and in individuals with significant obesity. Furthermore, administering a single injection reduces the psychological burden on treated patients (fear of needles), and consequently, can improve patient compliance.
Conclusion
The product Hyruan One combines new hyaluronic acid cross-linking technology, high biological stability, viscoelasticity, proven clinical efficacy, and more convenient administration. It thus brings a number of advantages for the pharmacological management of osteoarthritis.
(zza)
Source: Drápal V. Therapeutic benefits of Hyruan ONE®, a single intra-articular injection of hyaluronic acid: What does it address?
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.